

statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel,<sup>2</sup> solely for cybersecurity purposes. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.<sup>3</sup>

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of §§ 201.10 and 210.8(c) of the Commission's Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)).

By order of the Commission.

Issued: February 1, 2021.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2021-02435 Filed 2-4-21; 8:45 am]

**BILLING CODE 7020-02-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-772]

#### Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA, LLC

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Sterling Pharma USA LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written

<sup>2</sup> All contract personnel will sign appropriate nondisclosure agreements.

<sup>3</sup> Electronic Document Information System (EDIS): <https://edis.usitc.gov>.

comments on or objections to the issuance of the proposed registration on or before April 6, 2021. Such persons may also file a written request for a hearing on the application on or before April 6, 2021.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on January 5, 2021, Sterling Pharma USA, LLC., 1001 Sheldon Drive, Suite 101, Cary, North Carolina 27513-2078, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Tetrahydrocannabinols .....	7370	I

The company plans to manufacture in bulk drug code 7370 (Tetrahydrocannabinols) exclusively from hemp extract, for distribution and sale to its customers. No other activity for this drug code is authorized for this registration.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2021-02455 Filed 2-4-21; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-771]

#### Bulk Manufacturer of Controlled Substances Application: Noramco, Inc.

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Noramco Inc has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 6, 2021. Such persons may also file a written request for a hearing on the application on or before April 6, 2021.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement

Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on November 3, 2020, Noramco Inc, 1550 Olympic Drive, Athens Georgia 30601, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid ....	2010	I
Marihuana Extract .....	7350	I
Marihuana .....	7360	I
Tetrahydrocannabinols .....	7370	I
Codeine-N-oxide .....	9053	I
Dihydromorphine .....	9145	I
Hydromorphinol .....	9301	I
Nabilone .....	7379	II
Codeine .....	9050	II
Dihydrocodeine .....	9120	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Hydrocodone .....	9193	II
Levorphanol .....	9220	II
Morphine .....	9300	II

The company plans to manufacture bulk active pharmaceutical ingredients (API) and reference standards for distribution to their customers.

In reference to drug codes 7350 (Marihuana Extract), 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetics. No other activities for these drugs are authorized for this registration.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2021-02454 Filed 2-4-21; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

[OMB Number 1125-NEW]

#### Agency Information Collection Activities; Proposed Collection; Comments Requested; FOIAxpress/ FOIA Public Access Link

**AGENCY:** Executive Office for Immigration Review, Department of Justice.

**ACTION:** 30-day notice.

**SUMMARY:** The Department of Justice (DOJ), Executive Office for Immigration Review (EOIR), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.